Cargando…
Partial response to erlotinib in a patient with imatinib-refractory sacral chordoma
BACKGROUND: Chordoma is a rare, slow growing and locally aggressive mesenchymal neoplasm with uncommon distant metastases. It is a chemo-resistant disease with surgery and radiotherapy being the mainstay in treatment of localized disease. In advanced disease imatinib has a role. We report a case of...
Autores principales: | Verma, Saurav, Vadlamani, Surya Prakash, Shamim, Shamim Ahmed, Barwad, Adarsh, Rastogi, Sameer, Raj, S. T. Arun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7733273/ https://www.ncbi.nlm.nih.gov/pubmed/33308288 http://dx.doi.org/10.1186/s13569-020-00149-1 |
Ejemplares similares
-
Early clinical and metabolic response to tazemetostat in advanced relapsed INI1 negative epithelioid sarcoma
por: Tansir, Ghazal, et al.
Publicado: (2021) -
Good and sustained response to pembrolizumab and pazopanib in advanced undifferentiated pleomorphic sarcoma: a case report
por: Arora, Shalabh, et al.
Publicado: (2020) -
Sustained Response of a Clivus Chordoma to Erlotinib after Imatinib Failure
por: Houessinon, Aline, et al.
Publicado: (2015) -
Challenges in the management of metastatic gastrointestinal stromal tumor in a patient with neurofibromatosis type 1: a case report
por: Bharath, B. G., et al.
Publicado: (2022) -
An Unusual Case of Synovial Sarcoma with Breast Metastasis: Findings on Positron Emission Tomography-Computed Tomography
por: Upadhyay, Avinash, et al.
Publicado: (2020)